Cite
HARVARD Citation
Sarlo, C. et al. (2013). Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy. Leukemia research and treatment. p. . [Online].